OKYO Pharma Limited Sponsored ADR (OKYO) has released an update.
OKYO Pharma Limited reports a 68% improvement in a Phase 2 trial of OK-101, a drug candidate for Dry Eye Disease (DED), showing potential for conjunctival staining and ocular pain as co-primary endpoints. The trial, which involved 240 patients, also demonstrated OK-101’s favorable tolerability and significant efficacy in reducing symptoms like ocular pain compared to a placebo. As a clinical-stage biopharmaceutical company, OKYO Pharma continues to focus on developing innovative treatments for DED and neuropathic corneal pain.
For further insights into OKYO stock, check out TipRanks’ Stock Analysis page.
